All 3 strengths of iron sucrose injection are expected to be available “imminently”. The Food and Drug Administration (FDA) has approved the first generic version of Venofer ® (iron sucrose) Injection ...

Expands access to much-needed iron therapy for millions of US patients Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches Strengthens US supply of ...

The Food and Drug Administration has given Viatris permission for iron sucrose injection, an intravenous iron replacement product used to treat iron deficiency anemia in adult and pediatric patients ...

(RTTNews) - Viatris (VTRS) announced the FDA has approved Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia in adult and pediatric patients with ...

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, ...

The US Food and Drug Administration (FDA) released new draft guidance for industry on 27 March entitled Bioequivalence (BE) Recommendations for Iron Sucrose. The guidance instructs industry how to ...

This story is free to read because readers choose to support LAist. If you find value in independent local reporting, make a donation to power our newsroom today. Shannon Wood Rothenberg walked into ...

Amphastar Pharmaceuticals, Inc. AMPH, a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, ...

Intravenous (IV) iron use overall is associated with a “very low” risk for anaphylaxis, but iron dextran and ferumoxytol carry an increased risk relative to iron sucrose, according to new research.

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Viatris Inc. is one of them. Viatris Inc. (NASDAQ:VTRS), formed from the 2020 merger of Mylan ...

During a period of rapid fluctuation in the intravenous iron market, there was increased use of a more expensive drug that afforded providers additional revenue. Objectives: Medicare Part B payment ...